Evaluating single cell omics to understand the heterogeneity in immune and tumor cellsMulti-omic biomarkers for patient selection in solid tumor IO: is there a path to more personalized therapy?In an era of ‘targeted’ therapies against cell-intrinsic mechanisms (e.g. PARP, NTRK, BRAF) and surface molecules (Nectin-4, HER2), is there a path forward for pan-tumor biomarkers, or is multi-tumor more likely to be the dominant development mechanism?

Moderated by:

Theresa LaVallee, PhD, VP, Translational Medicine and Regulatory Affairs, Parker Institute for Cancer Immunotherapy

Panelists:

Jared Lunceford, PhD, Distinguished Scientist, Biostatistics and Research Decision Sciences, Merck Research LaboratoriesAngel A Rodriguez, MD, Oncology Medical Director, NateraSamik Upadhaya, PhD, Research Analyst, Anna-Maria Kellen Clinical Accelerator and Venture Fund, Cancer Research Institute (CRI)

Learn more about the IO360° Summit at www.io360summit.com